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Abstract
Background and aim
Numerous outcome studies and interventional trials in hemodialysis (HD) patients are
based on uremic toxin concentrations determined at one single or a limited number of time
points. The reliability of these studies however entirely depends on how representative
these cross-sectional concentrations are. We therefore investigated the variability of predia-
lysis concentrations of uremic toxins over time.
Methods
Prospectively collected predialysis serum samples of the midweek session of week 0, 1, 2,
3, 4, 8, 12, and 16 were analyzed for a panel of uremic toxins in stable chronic HD patients
(N = 18) while maintaining dialyzer type and dialysis mode during the study period.
Results
Concentrations of the analyzed uremic toxins varied substantially between individuals, but
also within stable HD patients (intra-patient variability). For urea, creatinine, beta-2-micro-
globulin, and some protein-bound uremic toxins, Intra-class Correlation Coefficient (ICC)
was higher than 0.7. However, for phosphorus, uric acid, symmetric and asymmetric
dimethylarginine, and the protein-bound toxins hippuric acid and indoxyl sulfate, ICC values
were below 0.7, implying a concentration variability within the individual patient even
exceeding 65% of the observed inter-patient variability.
Conclusion
Intra-patient variability may affect the interpretation of the association between a single con-
centration of certain uremic toxins and outcomes. When performing future outcome and
interventional studies with uremic toxins other than described here, one should quantify
their intra-patient variability and take into account that for solutes with a large intra-patient
variability associations could be missed.
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Introduction
Chronic kidney disease is characterized by the retention of numerous solutes, which are
at the origin of a deterioration of multiple biochemical and physiological functions [1, 2].
In order to decrease these concentrations on the long term, and with it their biological
toxicity, interventions interacting on the generation and/or removal of these uremic tox-
ins have repeatedly been explored. In hemodialysis patients, numerous cross-sectional
studies evaluated the association of a single concentration of a specific uremic toxin(s)
with patient outcomes [3–9]. Also, various interventional studies investigated the impact
of a change in dialysis prescription on different toxin concentrations based on a limited
number of measurements [10–14]. However, a substantial spontaneous background fluc-
tuation of concentrations of uremic toxins within one patient over time might have an
impact on the interpretation of this type of studies, whereby the effect can be both over-
or underestimated purely based on chance.
Up till now, it has not been investigated in a systematic way whether predialysis concentra-
tions of uremic toxins remain constant in stable hemodialysis patients over a given time
period. The present study aimed at evaluating: 1) the intra-patient variability over time in com-
parison with the inter-patient variability of concentrations of a panel of uremic toxins; and 2)
the impact on concentration variability of patient-related and/or dialysis-related characteris-
tics. We therefore quantified the variability of predialysis uremic toxin concentrations in
hemodialysis patients over a period of 16 weeks.
Methods
Patients and dialyses
The study included eighteen stable chronic hemodialysis patients (3 women, 11 with diabe-
tes mellitus) of 72.5±10.1 years old, 55.7±30.1 months on dialysis, and with a residual renal
function (as calculated from the arithmetic mean of the creatinine and urea clearance [15])
of 3.5±3.0mL/min. Twelve patients had a well-functioning arteriovenous fistula as vascular
access, five patients a Palindrome 14.5F double lumen central venous catheter (Covidien,
USA), and one patient had a synthetic graft combined with a single lumen Tesio 12F central
venous catheter (Medcomp, USA). Monthly monitoring of the access flow showed no access
recirculation in the arteriovenous fistulae. Exclusion criteria were pregnancy, unstable con-
dition, vascular access problems, and age below 18. The study was designed according the
Declaration of Helsinki, approved by the local Ethics Committee, and written informed
consent was obtained from all participants (Ghent University Hospital: EC2012/603;
B670201214999).
The study period lasted for 16 weeks with a test session on midweek 0, 1, 2, 3, 4, 8, 12,
and 16. During the entire study period (i.e. for all patients lasting from September to Janu-
ary), the dialysis mode, dialyzer blood and dialysate flows and hemodialyzer type were
maintained stable in each patient, i.e. two-needle/lumen post dilution hemodiafiltration
(except in one patient who received hemodialysis) with high flux dialyzers: FX800 (n = 12)
(Fresenius Medical Care, Germany), Phylter HF 17G (n = 2) (Bellco, Italy), Sureflux 170
(n = 1) (Nipro Europe, Belgium), Xenium 210 (n = 1), Polyflux 170H (n = 1) and Evodial
1.3 (n = 1) (all three from Baxter, USA). During the test sessions, blood and dialysate flows
were 311±21 and 530±39mL/min, respectively, while ultrafiltration (i.e. referring to the
weight loss of the patient during dialysis) was set according to the need of the patient and
could vary over the study period. Kt/Vurea was monthly assessed using the single pool Dau-
girdas formula [16].
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Sampling and analysis
At the midweek test sessions, blood samples (Venosafe, gel+clot act.; Terumo Europe N.V.,
Leuven, Belgium) were collected predialysis from the vascular access and were centrifuged
after 20-30min to allow clotting (10min at 1250g, 4˚C), after which the serum was aliquoted
and stored at -80˚C until batch analysis within 3 months after the last sample collection. We
previously showed that the detected concentrations of uremic toxins is not influenced by a sin-
gle freeze/thaw cycle [17].
Urea (molecular weight MW: 60Da), creatinine (Crea, 113Da), and phosphorus (P, 31Da)
were measured by standard laboratory methods in the routine laboratory of the Ghent Univer-
sity Hospital, assuring measurement reproducibility. Urea was determined by Cobas c701(a
+b) urease UV kinetic measurement (Roche, Switzerland), creatinine by a Cobas c systems
2012–02 V10 Enzymatic modified Jaffe´ method (Roche, Switzerland), and phosphorus by
Cobas c701(a+b) molybdaat UV (Roche, Switzerland).
Other solutes were determined by reversed-phase high performance liquid chromatography
(RP-HPLC), as described earlier [13, 18]. These included uric acid (UA, 168Da), and the pro-
tein-bound solutes p-cresylglucuronide (PCG, 284Da), hippuric acid (HA, 179Da), indole acetic
acid (IAA, 175Da), indoxyl sulfate (IS, 213Da), p-cresylsulfate (PCS, 187Da), and 3-carboxy-4-
methyl-5-propyl-2-furanpropionic acid (CMPF, 240Da). To determine the total concentration,
serum samples were first deproteinized by heat denaturation (95˚C, 30 min). After heating, the
samples were placed on ice for 10 minutes. Subsequently, the samples were centrifuged (7379 x
g, 10 min) and filtered (3615 x g, 20 min, room temperature) through Amicon Ultra 0.5 mL Fil-
ters (molecular weight cut-off 30 kDa, Merck KGaA, Darmstadt, Germany). With HPLC, HA
and CMPF were analyzed by UV detection at 254nm, and UA at 300nm, whereas pCG and pCS
(λexc = 265nm, λem = 290nm) and IAA and IS (λexc = 280nm, λem = 340nm) were determined
by fluorescence detection [13, 18]. To obtain free fractions, untreated serum samples were fil-
tered through a Centrifree1 filter device (Millipore Billerica, MA, USA) prior to heating.
Recent validation of our HPLC analysis method showed intra-day precision (% relative
standard deviation; RSD) for UA, pCG, HA, IAA, IS, PCS and CMPF of 1.92, 2.39, 1.99, 2.56,
2.58, 2.52, and 8.59%, respectively, and an inter-day precision of 3.65, 6.38, 3.24, 6.34, 4.84,
5.95, and 11,57%, respectively, in pooled samples from CKD patients.
Enzyme-linked immunosorbent assay (ELISA) kits manufactured by DLD Diagnostika
GmbH (Hamburg, Germany) were used to quantify symmetric dimethylarginine (SDMA) and
asymmetric dimethylarginine (ADMA) (both MW 202Da). For beta-2-microglobulin (β2M)
(11800Da), ELISA kits of Orgentec Diagnostika GmbH (Mainz, Germany) were used. Manu-
facturer’s data report intra-assay coefficient of variation between 3.8–4.9% for β2M, 4.7–6.1%
for SDMA, 5.and 7–6.8% for ADMA.
Statistical analysis
For all concentrations and based on a linear mixed model that accounted for differences in
gender, age, BMI, dialysis vintage, Kt/V, UF (ultrafiltration), RRF (residual renal function),
and DM (diabetes mellitus) via the inclusion of covariates, the Intra-class Correlation Coeffi-
cient (ICC) was calculated as ICC = (inter-patient variability)2 / [(inter-patient variability)2 +
(intra-patient variability)2] = inter-patient variance / (inter-patient variance + intra-patient
variance). A threshold of ICC0.7 was assumed [19], corresponding to an intra-patient vari-
ability of maximum 65% of inter-patient variability (as derived from the above mentioned
equation).
The covariates (gender, age, BMI, dialysis vintage, Kt/V, UF, RRF, and DM) were checked
for independency by a correlation analysis.
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In the calculation of the ICC, administration of antibiotics was considered in cases when
blood sampling was performed at least 2 days after the first antibiotics intake, and in the statis-
tical analysis, the effect of the antibiotics was assumed to last until the end of the study.
Time was entered in the mixed model via dummy variables to check for any type of trend
over time. Via a model comparison with and without time the effect of time was assessed.
Relations between uremic toxin concentrations with patient and dialysis characteristics (i.e.
gender, age, BMI, dialysis vintage, Kt/V, UF, RRF, and DM) were checked via the mixed
models.
Results
At the start of the study period, patients had a BMI of 25.2±2.9 and single pool Kt/V of 1.5
±0.3.
Concentrations of different studied uremic toxins in the 18 patients highlight the substan-
tial inter-patient variability (Fig 1). In Fig 2, concentrations are centered per patient (mean
was set at zero within subjects and SD = 1; y-axis). By aligning the different patients, the intra-
patient variability is illustrated. The variability around the median (bold line) is patient depen-
dent and not in the same range for the different studied uremic toxins.
Table 1 shows the Intra-class Correlation Coefficients (ICCs), the overall average toxin con-
centration, and the inter- and intra-patient variances. ICC was corrected for gender, age, BMI,
dialysis vintage, Kt/V, UF (ultrafiltration), RRF (residual renal function), and diabetes status,
and was accounted for antibiotic administrations. For urea, creatinine, β2M, and some pro-
tein-bound uremic toxins (total concentrations of PCG, IAA, PCS, and CMPF; and all free
fractions except for HA), ICC was higher than 0.7 indicating that the intra-patient variability
was less than 65% of the inter-patient variability. For phosphorus, UA, SDMA, ADMA, and
the protein-bound toxins HA (total) and IS (total and free concentrations), however, ICC val-
ues range between 0.5 and 0.7 implying a substantial concentration variability within the
patient.
During the study period, 8 patients received antibiotics (Table 2 and Fig 3). No significant
differences were found between the ICC values with or without accounting for antibiotics ther-
apy, although in 4 out of 8 patients, effects of antibiotic therapy on concentrations of PCS and/
or IS can be observed (Fig 3).
Since concentrations for patient 6 were more than 2 SDs larger than the overall mean con-
centration for free IAA, free PCS, total CMPF and free IS, patient 6 could be assumed being an
outlier. However, differences in ICC were less than 10% with or without considering patient 6,
except for the free fractions of IS and PCS (decrease of ICC by 19 and 27%, respectively).
No trend over time was noticed for the different uremic toxin concentrations, except for
β2-microglobulin with slightly increasing concentrations (0.02mg/mL) over the 16 weeks
(P<0.001).
The concentrations of none of the uraemic toxins did show any relation with patient and
dialysis characteristics after adjusting for multiple testing.
Discussion
The present study investigated how intra-patient variability over time is related to the inter-
patient variability of concentrations of different uremic toxins in stable hemodialysis patients,
and whether these variabilities are influenced by patient and/or dialysis related characteristics.
Eighteen stable hemodialysis patients were followed during 16 weeks and predialysis midweek
blood samples were analyzed for different levels of uremic toxins.
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Our main findings are that 1) intra-patient variability was most pronounced for phospho-
rus, SDMA, ADMA, UA, total and free HA and total IS, 2) antibiotics did not play a significant
role in the overall concentration variability but seemed to have an impact in some individuals,
and 3) no consequent relation was found between toxin concentrations and different patient
and dialysis related characteristics.
Fig 1. Inter-patient variability. Box plots of predialysis serum concentrations on the respective original scales (y-axis) over the 18 patients (x-axis):
Crea (creatinine), phosphorus, total HA (hippuric acid), total IS (indoxyl sulfate), total PCS (p-cresylsulfate), and β2M (beta-2-microglobulin).
https://doi.org/10.1371/journal.pone.0186010.g001
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Fig 2. Intra-patient variability. Box plots of predialysis serum concentrations, re-scaled in such a way that within patients (x-axis) the mean is 0 and that
over the patients the SD = 1 (y-axis): for Crea (creatinine), phosphorus, total HA (hippuric acid), total IS (indoxyl sulfate), total PCS (p-cresylsulfate), and
β2M (beta-2-microglobulin).
https://doi.org/10.1371/journal.pone.0186010.g002
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With variations up to 4 SDs, an important inter-patient variability for all studied solutes
was demonstrated. Based on a previous multifactor analysis in 71 patients, the inter-patient
variabilities found in the present study could for different toxins be attributed to differences in
PNA between the individual patients [15]. In addition, since several of these uremic toxins
(PCS and IS) are from colonic origin, variation and changes in the composition and metabolic
function of the gut microbiota might play a role affecting generation [20]. And it is known that
gut microbiota composition is influenced by many factors characteristic for hemodialysis
patients such as older age, medication (antibiotics), nutrition, and exercise [21]. However the
link between toxin concentration and specific microbiota in CKD needs further investigation.
Table 1. Intra-class correlation coefficients (ICC) corrected for different covariates, with overall toxin average concentration, and inter- and intra-
patient variances.
toxin ICC average inter-patient variance intra-patient variance
urea 0.74 99.6 606 207
creatinine 0.75 6.98 0.685 0.232
phosphorus 0.58 1.39 0.048 0.035
SDMA 0.69 0.89 0.035 0.015
ADMA 0.69 2.63 0.290 0.128
UA 0.64 7.09 0.911 0.509
PCG 0.86 0.72 0.455 0.075
HA 0.50 3.50 1.616 1.586
IAA 0.81 0.21 0.033 0.008
IS 0.63 2.05 0.237 0.137
PCS 0.79 3.06 1.821 0.475
CMPF 0.94 0.33 0.109 0.007
Free PCG 0.85 0.65 0.378 0.068
Free HA 0.55 2.15 1.095 0.881
Free IAA 0.84 0.07 0.006 0.001
Free IS 0.83 0.15 0.011 0.002
Free PCS 0.85 0.19 0.030 0.005
β2M 0.76 2.64 0.317 0.101
ICC < 0.70 is indicated in bold; all average concentrations in mg/dL except phosphorus (mmol/L), SDMA and ADMA (both μmol/L) and β2M (mg/mL).
SDMA: symmetric dimethylarginin; ADMA: asymmetric dimethylarginin; UA: uric acid; PCG: p-cresylglucuronide; HA: hippuric acid; IAA: indole acetic acid;
IS: indoxyl sulfate; PCS: p-cresylsulfate; CMPF: 3-carboxy-4-methyl-5-propyl-2furanpropionic acid; β2M: beta-2-microglobulin
https://doi.org/10.1371/journal.pone.0186010.t001
Table 2. Antibiotics therapy.
patient Start of administration
(study week)
Duration
(days)
antibiotics
6 Before study start continuous Temocillin 2g (3x/week postdialysis)
7 0 5 amoxicillin 500mg + clavulanic acid 125mg (3/day)
10 3 6 amoxicillin 500mg + clavulanic acid 125mg (3/day)
10 12 21 amoxicillin 500mg (3/day)
11 12 5 amoxicillin 500mg + clavulanic acid 125mg (3/day)
14 8 16 amoxicillin 500mg + clavulanic acid 125mg (3/day)
15 6 19 vancomycin (target > 25mg/L)
15 15 10 amoxicillin 500mg (3/day)
17 14 2 amoxicillin 2g + clavulanic acid 200mg (2/day)
18 8 14 amoxicillin 500mg + clavulanic acid 125mg (3/day)
https://doi.org/10.1371/journal.pone.0186010.t002
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Fig 3. Concentration profiles in patients on antibiotics for the protein-bound toxins PCG (p-cresylglu-
curonide), HA (hippuric acid), IAA (indole acetic acid), IS (indoxyl sulfate), PCS (p-cresylsulfate), and
CMPF (3-carboxy-4-methyl-5-propyl-2-furanpropionic acid). The antibiotics interval is indicated in grey
shadow and the time averaged concentration (TAC) per uremic toxin and per patient is added to the right side of
each graph. Concentrations in mg/dL, except phosphorus (mmol/L), SDMA and ADMA (both μmol/L) and β2M
(mg/mL).
https://doi.org/10.1371/journal.pone.0186010.g003
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It is however more difficult to explain the observed intra-patient variability. Since most
patient and dialysis related characteristics were constant in our study period of 16 weeks, age,
gender, diabetes mellitus, BMI, dialysis vintage, ultrafiltration nor Kt/V cannot explain the
observed variability. As we did not control for it, and as it is considered as an important
parameter impacting on uremic toxin concentrations, changes in nutritional intake might
account for some of the variability. A randomized controlled trial in 29 healthy controls
revealed that a high protein intake for 2 weeks resulted in an increase of plasma levels for IS,
while no difference was found for the other tryptophan metabolite IAA, and the phenolic com-
pounds PCS and PCG [22]. Furthermore, in a cross-over randomized trial in 31 patients
(SYNERGY), synbiotic therapy (i.e. co-administration of pre- and probiotics) over 6 weeks
resulted in a significant and potentially clinically important reduction in serum concentration
of PCS [23], whereas for IS, this decrease was only found in patients not on antibiotic treat-
ment. This is in analogy with previous findings of a decrease of serum concentrations of p-cre-
sol, the precursor of PCS, with synbiotic therapy [24, 25]. Our results are in line with these
studies, as they demonstrate deviating results for the two protein-bound solutes IS and PCS,
and thus support that nutrition, or factors affecting metabolism of ingested nutrients (e.g.
intestinal microbiota impacting amino acid processing) might play a substantial role in intra-
patient variability of serum concentrations of uremic toxins.
Some uremic toxins showing an important intra-patient variability in the present study, i.e.
UA, ADMA, SDMA, and IS, have repeatedly been associated with vascular damage and mor-
tality [6, 8, 26–28]. Since these outcome studies are based on cross-sectional blood sampling at
isolated time points, it might strengthen their reliability if, despite large intra-patient variabil-
ity, associations can be found. However, studies considering associations between concentra-
tions of highly variable toxins and outcome risk to miss significance due to the large intra-
patient variability.
On the other hand, previous longitudinal studies [11–14], investigating the impact of inter-
ventions on toxin concentrations in dialysis patients, are gaining importance since the here
called ‘stable’ solutes showed significant concentration changes due to the intervention, while
changes were unexplainably absent for solutes with an important intra-patient variability, like
HA and IS. Furthermore, the discrepancy in the behavior of solutes that were expected to
behave alike (like expected for PCS and IS), can now very likely be explained by differences in
intra-patient variability, as reported in this analysis.
The observed and here presented inter- and intra-patient variances allow the calculation of
sample sizes for future studies on these uremic toxins. Furthermore, these data can also be of
help to setup appropriate study designs, accounting for the relative importance of both
variances.
The present study included the classical blood parameters for HD patients (i.e. urea, creati-
nine, and phosphorus) as well as representative uremic toxins for each class, i.e. the small
water soluble solutes: uric acid, ADMA and SDMA; the middle molecule β2M, and the pro-
tein-bound solutes: pCG, HA, IAA, IS, pCS, and CMPF. This selection was made with special
interest for those toxins with already described associations with outcome in CKD [4–6, 8, 29–
32].
All samples collected during the 16 weeks were analyzed in batch. The observed variability
in concentrations can thus not substantially be attributed to changes in laboratory procedures,
and should thus mainly be originating from patient characteristics.
Another confounding factor is the fact that 8 out of 18 of the otherwise stable HD patients
needed antibiotic therapy during the follow-up period, which is to our opinion unavoidable in
studies in HD patients. Also in the synbiotic study by Rossi et al, around 30% of patients were
started on antibiotics at some time point during the study [23]. Furthermore, our sensitivity
Uremic toxin concentration variability in hemodialysis patients
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analysis including only patients not receiving any antibiotics did not change the conclusion
that there was substantial intra-patient variability in concentrations of different uremic toxins.
Studies on the impact of antibiotics on uremic toxins are relatively scant. A recent study by
Nazzal et al. suggested that indoxyl sulfate and p-cresylsulfate concentrations were decreased
at day 2 and day 5 after a single vancomycin administration in hemodialysis patients [33]. This
study however contained no untreated control group which might be a drawback in view of
the presently shown variability of indoxyl sulfate over time. To our knowledge, it has not been
established so far if, and to what extent, antibiotics impact on the variability in toxin concen-
trations, neither on how fast this effect would take on, or how long it would last.
One can postulate that the variability in free concentrations could be affected from the use
of antibiotics competing with the protein-bound uremic toxins in their binding to albumin.
We found however no differences in percentages of protein binding of the studied protein-
bound toxins after antibiotic administration versus baseline (data not shown).
In line with our findings, Nakazato et al also found high intra-patient variability in serum
phosphorus in a study on 384 HD patients who were followed for 11 years [34]. Interestingly,
they could link high concentration variability to poor general conditions and non-cardiac
mortality of their patients [34], although these authors did not offer a mechanistic explanation
for the mechanisms provoking this variability.
In conclusion, this study found, more or less as expected, a substantial inter-patient vari-
ability in uremic toxin concentrations among stable HD patients, but also a marked intra-
patient variability which might have an impact on evaluations on the association of concentra-
tions and outcomes, as well as on the interpretation of studies assessing the impact of interven-
tions on uremic solute concentrations. With respect to the latter, if changes in concentrations
in the individual patient in an A-B or B-A cross-over design are smaller than the intra-patient
variability presented in this paper, these random changes after intervention should be consid-
ered as ‘clinically irrelevant’. Alternatively, cross-over designs A-B-A and B-A-B could be used
to further highlight that indeed the intervention caused the change in concentration, and that
this change is wiped out by returning to the alternative strategy. Furthermore, when perform-
ing future outcome and interventional studies with uremic toxins other than described here,
one should quantify their intra-patient variability and take into account that for solutes with a
large intra-patients variability associations could be missed.
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